Form 4: Lisata Therapeutics Director Steven M. Klosk Reports Acquisition of Restricted Stock Units

Director Steven M. Klosk reports acquisition of 15,789 restricted stock units in Lisata Therapeutics, vesting on January 9, 2026.

Summary

• Steven M. Klosk, a director of Lisata Therapeutics, reported a transaction on January 9, 2025.
• He acquired 15,789 restricted stock units (RSUs) under the company's 2018 Equity Incentive Compensation Plan.
• These RSUs will vest on January 9, 2026.
• Following the transaction, Klosk beneficially owns 65,359 shares of common stock, including 15,789 unvested RSUs.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard transaction of stock units to a director. It's neither overwhelmingly positive nor negative.

Positives

• The grant of restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grant of RSUs to a director can align their interests with shareholders, potentially leading to better company performance.
• Employees may view this as a positive sign of investment in leadership.

Key Dates